Maze Therapeutics, Inc. (MAZE)

Market Cap	2.13B
Revenue (ttm)	n/a
Net Income (ttm)	-101.46M
Shares Out	48.12M
EPS (ttm)	-3.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	548,272
Open	45.83
Previous Close	46.20
Day's Range	43.26 - 47.36
52-Week Range	6.71 - 47.36
Beta	n/a
Analysts	Strong Buy
Price Target	42.29 (-4.47%)
Earnings Date	Feb 14, 2026

About MAZE

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2025
• Employees: 125
• Stock Exchange: NASDAQ
• Ticker Symbol: MAZE
• Website: https://www.mazetx.com

Analyst Summary

According to 7 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $42.29, which is a decrease of -4.47% from the latest price.

Price Target

$42.29

(-4.47% downside)

Analyst Consensus: Strong Buy